Skip to content

Phathom Pharmaceuticals

US · PHAT #3684 by market cap Listed 2019
6.75 -0.07 -0.95%
Live - 5344 symbols - heartbeat 498s ago · 2026-10-08 10:00
Pre-market 7.00 +2.79%
After-hours 6.80 -0.15%
Market cap
545.68M
P/B
-1.59
EPS
-3.03
Reader sentiment Are you bullish or bearish on PHAT?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Raymond James Initiates Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $28
    Market Newswire · 2025/12/12
  • Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $0.00 per Share, Vs. FactSet Est of $-0.19
    MT Newswires · 2026/7/30
  • Rating change
    Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating
    Market Newswire · 2026/7/14
  • Rating change
    Barclays Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $18
    Market Newswire · 2026/5/15
  • Barclays Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $14
    Market Newswire · 2026/8/17
  • Rating change
    Raymond James Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $21
    Market Newswire · 2026/7/31
  • H.C. Wainwright Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)
    TipRanks · 2026/9/22
  • Rating change
    A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $25 to $28
    Market Newswire · 2026/5/1
  • Rating change
    Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $20
    Market Newswire · 2026/7/31
  • Rating change
    A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $13 to $28
    Market Newswire · 2026/2/27
  • Rating change
    Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Raises Target Price to $25
    Market Newswire · 2026/2/27
  • Rating change
    Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28
    Market Newswire · 2026/7/22
  • Rating change
    Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/7/22
  • Rating change
    Cantor Fitzgerald Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $29
    Market Newswire · 2026/1/14
  • Rating change
    Stifel Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28
    Market Newswire · 2026/1/15
  • Rating change
    Barclays Upgrades Phathom Pharmaceuticals(PHAT.US) to Buy Rating, Raises Target Price to $18
    Market Newswire · 2026/3/27
  • Leerink Partners Initiates Phathom Pharmaceuticals(PHAT.US) With Hold Rating, Announces Target Price $10
    Market Newswire · 2026/9/9
  • H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26
    Market Newswire · 2026/9/22
  • Rating change
    Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $22
    Market Newswire · 2026/7/31
  • Rating change
    Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $22
    Market Newswire · 2026/7/31

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 10:00:25 · For reference only, not investment advice and not tailored to your situation.